Cellzome strengthens management team
This article was originally published in Scrip
Cellzome, a US drug discovery company focused on kinase-targeted treatments for inflammatory diseases, has appointed Dr Oliver Rausch senior director of biology and Dr Andrew Ratcliffe director of chemistry. Dr Rausch has 10 years' experience in the pharmaceutical industry, five of which were with UCB Celltech, most recently as director of biology. Dr Ratcliffe has drug discovery experience in inflammatory/respiratory diseases and has been with UCB Celltech for nine years, six of which were as associate director of medicinal chemistry. The appointments follow the announcement earlier this month of Cellzome's agreement with GlaxoSmithKline to develop therapies for inflammatory diseases.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.